sacituzumab govitecan-hziy (Trodelvy)
Jump to navigation
Jump to search
Indications
- triple-negative metastatic breast cancer*
* previously treated with at least two other cancer regimens
Contraindications
Adverse effects
- most common
- nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash, abdominal pain
- risk of severe neutropenia (monitor, consider fligrastim)
Mechanism of action
- trop-2 directed antibody & topoisomerase inhibitor drug conjugate
Notes
- progression-free survival 5.6 months vs 1.7 months for single agent chemotherapy in women without brain metastases[2]
More general terms
References
- ↑ FDA News Release. April 22, 20202 FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments. https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments
- ↑ 2.0 2.1 Bardia A, Hurvitz SA, Tolaney SM et al Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 Apr 22;384(16):1529-1541 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33882206 https://www.nejm.org/do/10.1056/NEJMdo005998/full/